GLP-1 receptor agonist: difference between revisions
Diff·revision 31 → 32·13:59, 21 Oct 2025
Difference between revision 31 and revision 32 of GLP-1 receptor agonist. 2 lines changed; the page grew by 116 bytes.
| Revision 31 — 23:04, 1 Oct 2025 BatchNumberBede (talk) add category for the drug class 11,148 bytes ±0 | Revision 32 — 13:59, 21 Oct 2025 Chromatokid (talk) de-orphan 11,264 bytes +116 | ||
|---|---|---|---|
| 65 | Documentation supplied with such material varies from a full lot-specific [[Certificate of analysis|certificate of analysis]] with named methods to a single unattributed purity figure. A purity figure alone is not sufficient to characterise a peptide: without a [[Peptide content|peptide content]] determination and a water figure, the mass of active substance in a vial cannot be calculated, and a nominal 5 mg vial may contain substantially less. [[Underfilling|Underfilling]] is documented in independently tested material.{{r|reports}} | 65 | Documentation supplied with such material varies from a full lot-specific [[Certificate of analysis|certificate of analysis]] with named methods to a single unattributed purity figure. A purity figure alone is not sufficient to characterise a peptide: without a [[Peptide content|peptide content]] determination and a water figure, the mass of active substance in a vial cannot be calculated, and a nominal 5 mg vial may contain substantially less. [[Underfilling|Underfilling]] is documented in independently tested material.{{r|reports}} |
| 66 | 66 | ||
| + | 67 | This wiki records what submitted documents say and does not represent any such material as suitable for human use. | |
| + | 68 | ||
| 67 | == References == | 69 | == References == |
| 68 | {{reflist}} | 70 | {{reflist}} |